Clinical study on the combined effectiveness of Mashasaptaka Kwatha and Marsha Nasya with Mashasaptaka Taila in Pakshaghata (cerebrovascular accident-infarct)

Background: Pakshaghata is one among Vataja Nanatmaja Vyadhis which are considered as Mahavyadhis. Pakshaghata can be correlated with Hemiplegia, the commonest pathology of which is cerebrovascular accident (stroke). Stroke is defined as sudden onset of neurologic deficit from vascular mechanism. 85% of all strokes are ischemic and 15% are hemorrhagic. Aims And Objectives: To evaluate the combined effectiveness of Mashasaptaka Kwatha and Marsha Nasya with Mashasaptaka Taila in the management of Pakshaghata (Cerebrovascular Accident-infarct). Methods: Thirty diagnosed subjects of Pakshaghata (CVA due to infarct) were administered with Mashasaptaka Kwatha and Marsha Nasya with Mashasaptaka Taila for 7 days. The data of patients was recorded before and after treatment using an elaborate proforma. Assessment was done based on the primary and secondary outcome measures. For statistical analysis, Wilcoxon Signed Rank test, McNemar tests were used. Results: In this study it was found that there was statistically significant relief in the symptoms of Pakshaghata (Cerbrovascular accident-infarct). Conclusion: Relief in the symptoms was achieved by the drugs having properties such as Vatakaphahara, Anulomana, Brimhana, Srotoshodhana etc. Hence, Mashasaptaka Kwatha and Marsha Nasya with Mashasaptaka Taila for 7 days is effective in the management of Pakshaghata (Cerebrovascular accident-infarct)

An open label single arm prospective clinical study on Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana in Pakshaghata (CVA due to Infarct)

Background: Pakshaghata is one among the 80 vataja nanatmaja vikara and is a roga of madhyama roga marga. Vatavyadhi is considered to be one among the ashta mahagadas. Vatagajankusha rasa is a combination of vyosha, bhasmas, vatsanabha, karkatasringi, haritaki etc. It has vatakaphahara, vikasi, vyavayi, rasayana etc properties. It is said to be effective in treating pakshaghata in 7 days if given along with Pippali churna and Manjishta kwatha. Aims and Objectives: To evaluate the efficacy of Vatagajankusha rasa with Pippali churna and Manjishta kwatha as anupana in the management of pakshaghata (CVA due to infarct). Methodology: Among 32 registered patients, 30 completed the course of treatment. They were administered with Vatagajankusha rasa 1 tablet (125 mg) after food with anupana 3gm Pippali churna and 15 ml Manjishta kwatha twice daily (morning and evening) for a period of 7 days. Nominal & ordinal data were analysed using non parametric tests like McNemar and Wilcoxon’s signed rank tests respectively. Result: There was statistically significant improvement in the primary and secondary outcome measures (p<0.05 was observed). Conclusion: Vatagajankusha rasa with Pippali churna and Manjishta kwatha as anupana is effective in the management of Pakshaghata (CVA due to infarct)

Critical analysis of Siravyadhana in pain management of Raktavrutavataja Gridhrasi – A Case Study

Gridhrasi is a major and common disease among Vatavyadhis. It is such a condition which hampers the quality of life of individual and affect the day to day activities. Raktaavarana to Vata causes Shoola and Daha in a patient of Gridhrasi. Removing the Raktaavarana should be the prime concern in this case. A case of Raktavrutavataja Gridhrasi treated successfully with Siravyadhana is presented here

Hypertension Vis-à-Vis Vatavyadhi - A Critical Analysis

Hypertension (HTN or HT), also known as high blood pressure or arterial hypertension, is a chronic medical condition in which the blood pressure in the arteries is persistently elevated. Ranked as the third important risk factor for attributable burden of diseases in South Asia (2010). There are two basic components involved in the physiology of arterial blood pressure-cardiac output and peripheral resistance. Here hypertension has been understood on the grounds of Vatavyadhi and the management of hypertension on the same grounds has been elaborated. This paper throws an insight to the understanding and management of hypertension under the broad spectrum of Vatavyadhi. Also highlights the mode of action of anti-hypertensives on Ayurvedic grounds

An open label single arm prospective clinical study on Vatagajankusharasa with Pippali Churna and Manjishta Kwatha as Anupana in Gridhrasi (Sciatica)

Background - Low backache is the 2nd most common reason for all physician visits and it is a condition that affects as many as 80-90% of people during their life time.[1] Sciatica is a relatively common condition with a life time incidence varying from 13-40%. Gridhrasi in Ayurveda is a Rujapradhana Nanatmaja Vatavyadhi, which has similar presentation of sciatica intervenes with the functional ability of low back and lower limbs. Vata Gajankusha Rasa is a potent medicinal preparation, which in classics have mentioned can cure severe form of Gridhrasi in a week. The present study is taken up with the hypothesis that Vata Gajankusha Rasa with Manjishta Kwatha and Pippali Churna as Anupana would be effective in the management of Gridhrasi. Objective - To evaluate the effectiveness of Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana in the management of Gridhrasi (sciatica). Method - Among 40 registered patients 36 of them completed the course of treatment. They were administered with Vatagajankusha Rasa (125mg) twice daily with Pippali Churna (3grams) and Manjishta Kwatha (15ml) as Anupana before food for a period of 7 days. For stastistical analysis subjective and objective parameters were assessed by Wilcoxon signed rank and McNemar test. Result - In the parameters of Gridhrasi, the medicine was found to be statistically significant in relieving the assessment parameters like Ruk, Toda, Sthambha, Aruchi, Gourava (p<0.001). In Objective parameters like SLR and Lessagues test, significant relief was observed after statistical analysis. Conclusion - Vatagajankusha Rasa with Pippali Churna and Manjishta Kwatha as Anupana is effective in the management of symptoms of Gridhrasi

A Controlled Clinical Study to Evaluate the Comparative Effect of Anuloma DS Tablet and Lactitol + Ispaghula Powder in Functional Constipation

The International Classification of Diseases (ICD) has described constipation as decrease in normal frequencyof defecation accompanied by difficult or incomplete passage of stool and/or passage of excessively hard, dry stool (ICD10-CM-K59). Overall, the average prevalence of constipation in adults has been estimated as 16% worldwide (varies between0.7% and 79%); in adults aged 60 to 110 years, the prevalence has been estimated to be 33.5%. Objective: To evaluate andcompare the efficacy of tablet Anuloma DS and lactitol + ispaghula powder in constipation. Materials and methods: Sixty‐twosubjects with constipation were divided into two groups: Group A with 32 subjects and Group B with 30 subjects. Group Areceived 1 Anuloma DS tablet at bedtime and Group B received lactitol + ispaghula powder 5 g at bedtime for 15 days.Results: Twenty-eight patients in Group A showed significant improvement in stool consistency, whereas just 8 patientsshowed improvement in consistency of stool in Group B. Twenty patients showed improvement in frequency of stool inGroup A, whereas only 3 patients showed this improvement in Group B. Twenty-nine patients in Group A reported goodimprovement in feeling after defecation compared to 9 patients in Group B. Pain in abdomen improved in 21 patients inGroup A versus 9 patients in Group B. Improvements were also seen in scores on the Constipation Assessment Scale, PatientAssessment Scale, and Quality of Life Questionnaire. Conclusion: Anuloma DS showed significant clinical benefits in thetreatment of constipation compared to lactitol + ispaghula powder

A Controlled Clinical Study to Evaluate the Comparative Effect of Anuloma DS Tablet and Lactitol + Ispaghula Powder in Functional Constipation

: The International Classification of Diseases (ICD) has described constipation as decrease in normal frequencyof defecation accompanied by difficult or incomplete passage of stool and/or passage of excessively hard, dry stool (ICD10-CM-K59). Overall, the average prevalence of constipation in adults has been estimated as 16% worldwide (varies between0.7% and 79%); in adults aged 60 to 110 years, the prevalence has been estimated to be 33.5%. Objective: To evaluate andcompare the efficacy of tablet Anuloma DS and lactitol + ispaghula powder in constipation. Materials and methods: Sixty-twosubjects with constipation were divided into two groups: Group A with 32 subjects and Group B with 30 subjects. Group Areceived 1 Anuloma DS tablet at bedtime and Group B received lactitol + ispaghula powder 5 g at bedtime for 15 days.Results: Twenty-eight patients in Group A showed significant improvement in stool consistency of stool, whereas just8 patients showed improvement in consistency of stool in Group B. Twenty patients showed improvement in frequency ofstool in Group A, whereas only 3 patients showed this improvement in Group B. Twenty-nine patients in Group A reportedgood improvement in feeling after defecation compared to 9 patients in Group B. Pain in abdomen improved in 21 patientsin Group A versus 9 patients in Group B. Improvements were also seen in scores on the Constipation Assessment Scale,Patient Assessment Scale, and Quality of Life Questionnaire. Conclusion: Anuloma DS showed significant clinical benefitsin the treatment of constipation compared to lactitol + ispaghula powder

Combination of system biology to probe the anti-viral activity of andrographolide and its derivative against COVID-19

The present study aimed to investigate the binding affinity of andrographolide and its derivative i.e., 14-deoxy-11,12-didehydroandrographolide with targets related to COVID-19 and their probable role in regulating multiple pathways in COVID-19 infection. SMILES of both compounds were retrieved from the PubChem database and predicted for probably regulated proteins. The predicted proteins were queried in STRING to evaluate the protein-protein interaction, and modulated pathways were identified concerning the KEGG database. Drug-likeness and ADMET profile of each compound was evaluated using MolSoft and admetSAR 2.0, respectively. Molecular docking was carried using Autodock 4.0. Andrographolide and its derivative were predicted to have a high binding affinity with papain-like protease, coronavirus main proteinase, and spike protein. Molecular dynamics simulation studies were performed for each complex which suggested the strong binding affinities of both compounds with targets. Network pharmacology analysis revealed that both compounds modulated the immune system by regulating chemokine signaling, Rap1 signaling, cytokine-cytokine receptor interaction, MAPK signaling, NF-kappa B signaling, RAS signaling, p53 signaling, HIF-1 signaling, and natural killer cell-mediated cytotoxicity. The study suggests strong interaction of andrographolide and 14-deoxy-11,12-didehydroandrographolide against COVID-19 associated target proteins and exhibited different immunoregulatory pathways. This journal i